Basking Biosciences reports promising stroke therapy results
Basking Biosciences, a clinical-stage biopharmaceutical company developing a first-in-class, targeted, reversible thrombolytic therapy for acute ischemic stroke (AIS), has announced the publication of preclinical research in Communications Biology, a Nature Portfolio journal. The study shows that its lead candidate, BB-031, restores blood flow in a microfluidic model of arterial occlusion… Read More
